# Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female

> **NCT04407078** · NA · COMPLETED · sponsor: **Ajou University School of Medicine** · enrollment: 40 (actual)

## Conditions studied

- Gallbladder Diseases

## Interventions

- **DRUG:** Sugammadex Injectable Product
- **DRUG:** Neostigmine Injectable Product

## Key facts

- **NCT ID:** NCT04407078
- **Lead sponsor:** Ajou University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-02
- **Primary completion:** 2021-01-06
- **Final completion:** 2021-01-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04407078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04407078, "Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04407078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*